Anti-VEGF Receptor 2 antibody, prediluted (ab15292)


  • Product nameAnti-VEGF Receptor 2 antibody, prediluted
    See all VEGF Receptor 2 primary antibodies
  • Description
    Rabbit polyclonal to VEGF Receptor 2, prediluted
  • Tested applicationsSuitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide (unfortunately, the amino acid sequence is considered to be commercially sensitive) (Human) (C terminal).

  • Positive control
    • Angiosarcoma


Our Abpromise guarantee covers the use of ab15292 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notesIHC-P: Ready to use. Polyvalent-HRP-AEC detection system (biotin-streptavidin amplification system) is necessary. Perform heat-mediated antigen retrieval before commencing with IHC staining protocol, by boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10 min followed by cooling at RT for 20 min.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
    • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
      Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
      Contains 1 protein kinase domain.
    • Post-translational
      Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • CD309 antibody
      • CD309 antigen antibody
      • EC antibody
      • Fetal liver kinase 1 antibody
      • FLK-1 antibody
      • FLK1 antibody
      • FLK1, mouse, homolog of antibody
      • Kdr antibody
      • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
      • Kinase insert domain receptor antibody
      • KRD1 antibody
      • Ly73 antibody
      • Protein tyrosine kinase receptor FLK1 antibody
      • Protein-tyrosine kinase receptor flk-1 antibody
      • soluble VEGFR2 antibody
      • Tyrosine kinase growth factor receptor antibody
      • Vascular endothelial growth factor receptor 2 antibody
      • VEGFR 2 antibody
      • VEGFR antibody
      • VEGFR-2 antibody
      • VEGFR2 antibody
      • VGFR2_HUMAN antibody
      see all

    Anti-VEGF Receptor 2 antibody, prediluted images

    • ab15292, staining VEGF receptor 2 in human placenta by Immunohistochemistry (FFPE-sections).

    References for Anti-VEGF Receptor 2 antibody, prediluted (ab15292)

    ab15292 has not yet been referenced specifically in any publications.

    Product Wall

    I have just received the following information from the originator of ab15292:ab15292 was optimised with polyvalent-HRP-AEC detection system (biotin-streptavidin system). The originator suggests that that the detection system you are currently using ...

    Read More